CN1562036A - Nutrition supplement agent - Google Patents
Nutrition supplement agent Download PDFInfo
- Publication number
- CN1562036A CN1562036A CNA2004100339182A CN200410033918A CN1562036A CN 1562036 A CN1562036 A CN 1562036A CN A2004100339182 A CNA2004100339182 A CN A2004100339182A CN 200410033918 A CN200410033918 A CN 200410033918A CN 1562036 A CN1562036 A CN 1562036A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- calcium
- folic acid
- medicament
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000016709 nutrition Nutrition 0.000 title claims description 8
- 230000035764 nutrition Effects 0.000 title claims description 8
- 239000013589 supplement Substances 0.000 title description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 120
- 239000011724 folic acid Substances 0.000 claims abstract description 63
- 235000019152 folic acid Nutrition 0.000 claims abstract description 62
- 229960000304 folic acid Drugs 0.000 claims abstract description 59
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 58
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 24
- 229940046008 vitamin d Drugs 0.000 claims description 69
- 229930003316 Vitamin D Natural products 0.000 claims description 67
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 67
- 239000011710 vitamin D Substances 0.000 claims description 67
- 235000019166 vitamin D Nutrition 0.000 claims description 67
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 67
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 32
- 239000011575 calcium Substances 0.000 claims description 32
- 229960005069 calcium Drugs 0.000 claims description 32
- 229910052791 calcium Inorganic materials 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 25
- 229960003563 calcium carbonate Drugs 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 15
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- QXDHJHQRJCJRAU-UHFFFAOYSA-N calcium;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Ca].OC(=O)CC(O)(C(O)=O)CC(O)=O QXDHJHQRJCJRAU-UHFFFAOYSA-N 0.000 claims description 4
- 229940036630 folic acid 0.2 mg Drugs 0.000 claims description 4
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 235000001465 calcium Nutrition 0.000 description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 24
- 235000010216 calcium carbonate Nutrition 0.000 description 20
- 239000000203 mixture Substances 0.000 description 16
- 229920000881 Modified starch Polymers 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 229940032147 starch Drugs 0.000 description 14
- 235000019359 magnesium stearate Nutrition 0.000 description 12
- 208000007502 anemia Diseases 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 10
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
- 229910001424 calcium ion Inorganic materials 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000007442 rickets Diseases 0.000 description 7
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 6
- 206010016880 Folate deficiency Diseases 0.000 description 6
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000576 supplementary effect Effects 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 208000002720 Malnutrition Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001071 malnutrition Effects 0.000 description 5
- 235000000824 malnutrition Nutrition 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 208000015380 nutritional deficiency disease Diseases 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007779 soft material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010006956 Calcium deficiency Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 235000007635 levomefolic acid Nutrition 0.000 description 3
- 239000011578 levomefolic acid Substances 0.000 description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- -1 one carbon unit tetrahydrofolic acids Chemical class 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000010829 Spina bifida Diseases 0.000 description 2
- 208000006097 Spinal Dysraphism Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002320 anencephaly Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000252206 Cypriniformes Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000002281 placental hormone Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000001747 pteroyl group Chemical group [H]C1=C([H])C(C(=O)[*])=C([H])C([H])=C1N([H])C([H])([H])C1=C([H])N=C2N([H])C(N([H])[H])=NC(=O)C2=N1 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Abstract
A nutrients supplementing medicine contains folic acid, VD, calcium carbonate and auxiliaries.
Description
Technical field:
The present invention relates to a kind of supplementary, these supplement are by active component folic acid, vitamin D, and calcium carbonate and adjuvant are formed.
Background technology:
Folic acid is one of vitamin B group that the forties in last century, middle and late stage was separated, and rank in turn the 9th is owing to begin it is to extract to be able to using names from the leaf of Herba Spinaciae.In fact, folic acid is the general designation of one group of proximate chemical compound of the similar biochemical characteristic of chemical constitution, and it is " the many glutamic acid of pteroyl " that scientist gives its name, is mainly combined by pteridine, para-amino benzoic acid and glutamic acid three part materials.
The folic acid that is present in nature has dihydrofoilic acid and two kinds of forms of tetrahydrofolic acid, and in human body, have only tetrahydrofolic acid just to have physiological function, tetrahydrofolic acid is the carrier of one carbon unit, and one carbon unit is meant the gene that contains a carbon atom in the human body metabolic processes, methyl for example, methylol etc., these active one carbon unit tetrahydrofolic acids just, the generation and the metabolism of chemical compound lot have been participated in, for example various amino acid whose mutual conversions in the living matter, synthesizing of hereditary material DNA (deoxyribonucleic acid) (DNA), and hemoglobin, epinephrine, creatine, choline synthetic etc.
Contain 5-6 milligram folic acid among the normal human, wherein 50% be stored in liver.Folate content in the blood be subjected to the influence of recent food can height can be low, but erythrocytic folate content is more constant in the blood, can reflect the nutriture of human body folic acid.Red blood cell acidum folicum content reaches 140 micrograms per litre when above, illustrates that the human body folic acid nutrition is suitable, even if there is not the absorption of folic acid in the meals, also can keep the malnutrition that did not occur folic acid in 2-3 month.
Folic acid is to enliven the gene coenzyme most in the various enzymes, and the outstanding healthy reproduction problem of malnutrition women colony is birth defects such as nervus centralis dysplasia such as fetus anencephaly and spina bifida, even can be extended to the intelligence development obstacle behind the baby due.In addition, anemia also can cause pregnant women placental early to be shelled, pregnant high-risk disease such as preeclampsia.
Should, in a country in the majority based on agricultural, peasant, the food source of folic acid should not be deficient, the content of folic acid is all abundanter in animal livers, yeast, vegetable and the fruit.Be not difficult to find out that from the introduction of front the metabolism of folic acid is very active, it is met light and meets thermoae easy decomposition.It is a kind of water miscible vitamin B group, can lose in a large number in the process of cleaning, shred, cooking at food, and the biotic factor in the natural plants also can hinder the important member of human body to the family of folic acid, so from antibacterial, the virus that is invisible to the naked eye, really big thing in the mankind and the mammal, it has almost participated in the biochemical metabolism process of all life.What be worth describing in detail is the metabolic cycles of folic acid and methionine.The running of this typical-carbosilane unit carrier is that methionine becomes active methionine under the effect of adenosine triphosphate (ATP), and active methionine provides an one carbon unit methyl and forms homocysteine.The latter again with 5-methyl four ammonia folic acid in one carbon unit methyl synthetic methionine, make the 5-methyl tetrahydrofolate change tetrahydrofolic acid into.Tetrahydrofolic acid combines with the one carbon unit methyl that other biological chemical metabolization process generates again, forms the 5-methyl tetrahydrofolate again.The importance of folic acid in this metabolic cycles process is, if folic acid deficiency, the 5-methyl tetrahydrofolate is synthetic not enough, obstacle will take place to the conversion of methionine in homocysteine so, causing a series of diseases in succession now changes: homocysteine is piled up, cause the one carbon unit methyl to generate and reduce, this just directly influences the synthetic of more than 50 kind of important substance.The homocysteine of high concentration can damage the endotheliocyte of blood vessel, become important cardiovascular and cerebrovascular vessel paathogenic factor, homocysteine acts on responsive embryo's neurocyte, can cause irreversible lesion such as anencephaly and spina bifida, the homocysteine dissolubility is little, easily forms in conjunction with stopping up urinary system ... the malnutrition problem of folic acid causes widely therefrom to be paid close attention to.
Folic acid deficiency is an anemia for the known clinical manifestation of people early, and it is different with general iron deficiency anemia, and what stand in the breach harm is anemia of pregnant woman and fetus.At development of fertilized ova, when the cell division growth was very vigorous, metabolism was active, and protein synthesis quickens, and the requirement of folic acid suddenly increases severely.If red blood cell acidum folicum storage capacity deficiency in anemia of pregnant woman's body, the Placenta Hominis dysplasia will spontaneous abortion.The impaired the earliest position of dysontogenesis is exactly a nervus centralis.Since the eighties, the various countries scientist finds to absorb, experiment confirm, and the absorption of different modes, folic acid absorbance difference is very big, only takes about half of simple folic acid tablet usually with the folic acid absorbance that food is taken in.So more extensive although folic acid distributes in various food, human body can be achieved by a variety of factors absorbing of folic acid.More and more countries recommends resident (the particularly women of child-bearing age) will note in time augmenting as required folic acid, with disease preventing and treating, protect the health, improve the quality of living.
The discovery of vitamin D is the result of people and rickets fight.As far back as 1824, just the someone found that cod-liver oil can play an important role in the treatment rickets.1918, the prunus mume (sieb.) sieb.et zucc. orchid of Britain confirmed that than the jazz rickets is a kind of food deficiency disease.But he thinks it is to be deficient in vitamin due to the A by mistake.Up to the end of the twenties, the beginning of the thirties, people confirm that just vitamin D deficiency is to cause rachitic reason, and separate the vitamin D of having purified.
Vitamin D can make calcium and phosphorus be utilized effectively, makes strong skeleton and tooth; But take preventing cold simultaneously with vitamin A, C; Help treatment to conjunctivitis; Help to absorb vitamin A.
The vitamin D major part is synthetic in vivo, only the small part vitamin D
3Be from food.The subcutaneous steroid material of human body can form behind ultraviolet radiation.Picked-up all is indispensable in big sun of solarization and the food.
The major physiological function of vitamin D is: regulate calcium, phosphorus metabolism, promote calcium, phosphorus to absorb.During shortage, the child can cause rickets, general metabolism obstacle, dysplasia; The adult can cause osteomalacia, and anemia of pregnant woman and women breast-feeding their children are more obvious.
The baby is the population at risk of vitamin D deficiency, because need a large amount of relatively vitamin D during the quick growth promoter of health.During birth, the baby obtains and has stored a certain amount of vitamin D from parent, can satisfy the life needs of first few months afterwards.France shows that to neonatal survey result 64% baby 25-(OH) D is arranged in recent years
3This value of value＜30nmol/L has been the lower bound (Zeghund etc. of normal range, 1997). because vitamin D content is lower in the breast milk, so breast-fed babies more are prone to vitamin D deficiency (Specker etc., 1985) but the trophism rickets of breast-feeding infant still is rarely found, case often occurs in and lacks sunlit breast feeding babies (Pettifor and Daniels, 1997; Binet and Kooh, 1996; Brunvand and Nordshus, 1996; Gessner etc., 1997).Baby in the northern area of China birth in autumn, will be in the indoor time of spending 6 months, even embrace the baby to outdoor, that also the baby is wrapped up is very tight, make their skin that the chance of synthesis of vitamin d seldom be arranged, vitamin D deficiency (Yan Huaicheng etc.,, in 1986 in 1989) takes place in such child Geng Yi
Provide 8.75 μ g (350IU) vitamin D can prevent rachitic biochemical the variation every day at China's southern area infant, and just need 13.75 μ g (550IU) vitamin D (Wu Guangchi, 1989 years at the infant of northern area; Lee is equal, nineteen ninety).Although vitamin D deficiency is rare in developed country, still has in northern city and to distribute rachitic report, often breast-fed babies always.The cause of disease of children rachitis is removed the deficiency at sunshine, and the vitamin D that absorbs from food is not enough, and calcium phosphorus ration is improper, add to the baby prematurely outside the reason such as cereal, also with trimester of pregnancy parent the vitamin D malnutrition substantial connection is arranged.In infant formula, need to add the vitamin D of 0.2-0.6 μ g/100kj (9.6-23.9IU/100KJ).Sufficient vitamin D can prevent the rachitic generation of infant.
Adolescence is another stage that health is grown fast.In this stage, teenager is to the increase that needs of vitamin D.Teenager and baby are different, and they are usually movable out of doors, therefore can obtain sufficient ultraviolet radiation and come synthesis of vitamin d to satisfy the needs of self.Too much vitamin D mainly is stored in the fatty tissue in summer and time in the early autumn body, and this will help keeping in ensuing winter the normal speed of growth of health.In this period,, the health vitamin D may cause vitamin D deficiency if storing deficiency.
20 years in the past, the biochemical mechanism of vitamin D has been carried out more clinical research.The result shows, many key functions of vitamin D all with old and feeble relevant (Holick, 1994).Comprise that skin synthesis rate, formation have the conversion rateization of active hormone form and the reaction of target tissue (as bone), the minimizing (Shearer, 1997) that also has skin to expose.The problem of old people's vitamin D deficiency is with low 25-(OH) D in the blood
3Following the active rising in sea of blood plasma parathyroid hormone and alkali phosphatase is its feature (Gloth etc., nineteen ninety-five; Chapuy etc., 1997).Vitamin D deficiency can reduce old people's sclerotin, increases hip fracture incidence rate (Dawson-Hughes etc., 1997).The vitamin D intake (10-20 μ g/d) of several research groups having found suitably to increase can reduce bone loss and fracture incidence rate (Shearer, 1997; Chapuy and Meunier, 1997; Lips etc., 1996).Suitably increase the recommended intake of old people's vitamin D, be increased to and keep the normal 25-of old people (OH) D
3Level (Russell, 1997; Goulding, 1999) this can make middle age and old people's (＞70 years old) bone loss rate little of 10-15 μ g/ (kgd) (Report on Dietary Reference Intakes, 1997) respectively.Recent multinomial research all advises increasing old people's vitamin D intake, from 5 μ g/d or 15 μ g/d (RNI).
In women's pregnancy with between age of sucking, variation has taken place in the level of gonadal hormone in the body.The pregnancy period vitamin D Can produce certain effect to the anemia of pregnant woman, and to not effect age of sucking.Although the metabolism of pregnancy period vitamin D also changes to some extent, i.e. 1.25-(OH) in mother's blood plasma
2D
3Level increase, as if the reason of generally acknowledging is the synthetic effect of placental hormone (Delvin etc., 1985), can not produce great influence to parent vitamin D recommended amounts.May be still waiting to confirm to the deleterious view of fetus about the pregnancy period vitamin D Can, very important in view of after vitamin D is transported to fetus from parent to determining the neonatal speed of growth, therefore can't oppose to replenish an amount of vitamin D to the anemia of pregnant woman.In China, by giving conceived disposable vitamin D Can 100,000 IU of 28 all women or 200,000 IU and have no side effect (Yan Huaicheng, 1986).The vitamin D nutriture that this dosage can obviously improve the anemia of pregnant woman (comprises rising puerpera blood and umbilical blood 25-(OH) D
3Level, reduce the generation of pregnancy complications such as the reduction of PA blood calcium and anemia of pregnant woman's cramp in the leg), and help to prevent baby's congenital rickets (Wu Guangchi, 1992).
To women breast-feeding their children, vitamin D is directly effect not.The calcium requirement increase is the adjusting of special hormone before and after being given a birth, and research does not in recent years find what vitamin D metabolism has change (Prentice,, Jones etc. 1999 years in 1998) between age of sucking.Vitamin D level lower (Specker etc., 1985) in the breast milk, the vitamin D of parent does not have more consumption between age of sucking.And do not have evidence to show yet, replenish calcium for mother of suckling or vitamin D can increase calcium or vitamin D is transported to the intravital amount of neonate (Prentice, 1998).Present suggestion is to there is no need extra vitamin D Can between age of sucking, neonate in utero after, as long as can keep the good nutrition of parent, have sufficient sunlight to expose, just can guarantee normal vitamin D nutriture.
Human body ill symptoms because of calcium deficiency causes is confirmed.Calcium-enriched in food, be science, succinct, effective measures.We are by the large tracts of land census of population, find calcium deficiency and folic acid deficiency in human body and deposit, and both shortages have had a strong impact on people's health, and the simple medicine of replenishing the calcium is only arranged in the market, as Maalox Antacid, the compound formulation that vitamin D and calcium carbonate also arranged replenishes as calcium preparation, but is not Supplement of folic acid, replenish the medicament of calcium again simultaneously, for this reason, the invention provides a kind of like this medicament, promptly help health of people, also taking convenience has demonstrated good effect.
Summary of the invention:
The invention provides a kind of medicament of extra-nutrition, be made up of acceptable auxiliary on active component with Nutrition and the pharmaceutics, it is characterized in that, described active component with Nutrition is a folic acid, the combination of vitamin D class material and calcareous material.
Medicament of the present invention exists with unit dose, the active component folic acid 0.1-1.5mg that each dosage unit contains, and vitamin D class material 40-180IU, the utilizable calcium 100-800mg in the calcareous material, all the other are acceptable auxiliary on the pharmaceutics.Preferably consist of: folic acid 0.2-0.8mg, vitamin D class material 60-120IU, utilizable calcium 300-400mg in the calcareous material, most preferred consisting of: folic acid 0.2mg, vitamin D class material 80IU, utilizable calcium 386mg in the calcareous material, wherein vitamin D class material is preferably vitamin D
3, calcareous material is selected from calcium carbonate, calcium gluconate, Citric acid calcium, calcium lactate or threonic acid calcium.
Also comprise in this medicament medicine or food the adjuvant that can accept, medicament of the present invention exists with unit dosage form, described unit dosage form is meant the unit of preparation, as every of tablet, capsular every capsules, every of injection etc., in most preferred composition, contain in the medicament of per unit dosage:
Utilizable calcium 100-800mg
Folic acid 0.1-1.5mg
Vitamin D
340-180IU
Preferably
Utilizable calcium 300-400mg
Folic acid 0.2-0.8mg
Vitamin D
360-120IU
Most preferably
Utilizable calcium 386mg
Folic acid 0.2mg
Vitamin D
380IU
Wherein, utilizable calcium is meant the amount of calcium ion, for different calcium salts, can add different calcium salt amounts, but the amount of calcium ion wherein is above recipe quantity, for example calcium carbonate 1000g, wherein the calcium ion percentage ratio that accounts for weight of calcium carbonate is for smaller or equal to 40%, the amount of calcium ion is 300-400g (when calcium carbonate was pure product, the amount 40% of the calcium ion in the calcium carbonate then was lower than 40% when impure) in the general merchandise calcium carbonate.Vitamin D
3The employing iu is calculated, the analytically pure vitamin D of every 1ug
3Equal 40 iu IU, and the food stage vitamin D of selling on the market
3Not pure, therefore calculate the variation that to avoid intake with iu and utilizable calcium.
Raw material sources:
Yantai, Shandong, the calcium carbonate place of production
Jiangsu, the folic acid place of production
Vitamin D
3Place of production imported food additive is the Jiangsu packing
Compound basis of the present invention
This product is calcium and folic acid and vitamin D
3Supplementary.
Calcium is the important composition that constitutes human body, is the maximum inorganic elements of people's in-vivo content, accounts for the 1.5%-2.0% of body weight for humans.Calcium is the indispensable ingredient that constitutes the human body integrity, plays an important role to earning a bare living.Yet the picked-up of each crowd's calcium of a large amount of science investigation proof China is generally on the low side, only reaches about 50% of RDA, the intake wretched insufficiency of child, wet nurse, calcium especially, and the various illness that caused by calcium deficiency constantly take place.To the attention of primary health care work with popularize, people adjust with supplementary that the shortage of calcium comes into fashion in the body through government in the past few years.In addition, we also find the phenomenon of calcium deficiency and folic acid deficiency in the human body and deposit from a large amount of investigation.U.S. food and nutrition committee (FNB) proposed the folic acid dietary intake in 1998 should be with meals folic acid equivalent (DFE)=[meals folic acid ug+ (1.7=folic acid supplement ug)].
Folic acid activity form in vivo is a tetrahydrofolic acid, as one carbon unit (as methyl CH
3, subunit CH
2) coenzyme of transferring enzyme system, be indispensable important substance in amino acid metabolism and the nucleotides metabolism.Cell proliferation, tissue growth and body development all need enough folic acid.Epidemiological study shows, because folic acid deficiency causes the anemia of pregnant woman can produce teratogenesis in the human body, young and middle-aged cardiovascular and cerebrovascular disease increases.Generation according to relevant bibliographical information senile dementia is also relevant with folic acid deficiency, thereby this product collection calcium carbonate, micro-folic acid and mcg vitamin D
3For one as supplementary, be a kind of metal essence, the mix supplement agent of two kinds of vitaminss, and compatibility is reasonable, three kinds of compositions are complementary in vivo, can play a role for biochemical environment in the balanced body, thereby be a kind of desirable supplementarys reasonable, instant of filling a prescription.
Heavy dose of folic acid is the 5mg product, and is domestic as the Drug therapy anemia, because dosage is big, takes vitamin B for a long time
12Picked-up influential, also have the possibility excite other illness, and the content of folic acid is micro-in the medicament of the present invention, take suitable every day.
Medicament of the present invention can be any dosage form of taking usefulness, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, syrup, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch, slow releasing preparation, controlled release preparation.
Medicament of the present invention is that the active component of above-mentioned prescription and acceptable carrier (adjuvant) pharmaceutically or on the food are mixed, and is prepared from.
Medicament of the present invention, the tablet of its oral administration and capsule are generally a kind of unit dose, and contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active component is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active component prescription of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active component in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Prepare the parenteral suspension with essentially identical mode,, and before it is suspended in sterile carrier, it is carried out disinfection with oxirane except being is suspended in carrier with reactive compound rather than with its dissolving.Surfactant or wetting agent can be included in this compositions, are beneficial to the uniform distribution of this reactive compound.
Medicament of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, pregelatinized Starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
The preparation method of pharmaceutical preparation of the present invention can adopt following method:
As tablet: calcium carbonate and medical starch mix, the system soft material, and the system wet granular, dry 4 hours of 80-100 degree, the cooling back added folic acid, vitamin D
3, magnesium stearate, pregelatinized Starch mixes, granulate, tabletting, the bag film-coat, packing promptly gets tablet.
When preparation medicament of the present invention, should note following technical problem:
1, must be before supplementary material uses through qualified can the use of quality testing department chemical examination.Calcium carbonate, granularity＜10 μ.
2,100 mesh sieves are crossed in adjuvant, starch, pregelatinized Starch.
3, with calcium carbonate and starch, place blender, fully mix, add 15% starch slurry, be mixed to evenly.Granulate with 12 order nylon screens.
4, above-mentioned granule is placed in the drying baker, 80 ℃ of-100 ℃ of dryings reach disinfective action about 4 hours simultaneously.
5,, add folic acid, vitamin D equably with dried granules
3Adding magnesium stearate, pregelatinized Starch are carried out always mixing, and reach even back with 14 eye mesh screen granulate.
6, check granule content, it is heavy to calculate sheet, carries out tabletting, hangs film-coat.
7, packing after the assay was approved, vanning, warehouse-in.
Medicament of the present invention can be taken 1-6 time every day, and preferably 3 times, take a 1-6 preparation unit at every turn, as 1-6 sheet or 1-6 capsules, the child can according to circumstances reduce the dosage of taking.
Medicament of the present invention is for lacking disease that calcium and folic acid causes or malnutrition or uncomfortablely having a good adjusting, treatment and preventive effect, also can be used for hypertension, coronary heart disease, diabetes, lassitude, tired easily, pale complexion, forgetful, insomnia, retarded growths etc. have treatment and preventive effect, and medicament of the present invention is easy to absorb, and formulation method is simple, act on good, prescription complements each other mutually, has obtained good effect, feedback after relevant crowd's use is shown, be subjected to people's welcome deeply.
The specific embodiment:
Further specify the present invention by the following examples.
Embodiment 1:
The preparation of tablet
Calcium carbonate 1000kg
Folic acid 202g
Vitamin D
3880g (100,000 IU/g)
Medical starch 100kg
Magnesium stearate 10kg
Pregelatinized Starch 10kg
Calcium carbonate and medical starch mix, the system soft material, and the system wet granular, dry 4 hours of 80-100 degree, the cooling back added folic acid, vitamin D
3, magnesium stearate, pregelatinized Starch mixes, granulate, tabletting, the bag film-coat, packing promptly gets 1,000,000 in tablet.
Embodiment 2:
The preparation of capsule
Calcium carbonate 1000kg
Folic acid 202g
Vitamin D
3880g (100,000 IU/g)
Medical starch 100kg
Magnesium stearate 10kg
Pregelatinized Starch 10kg
Calcium carbonate and medical starch mix, the system soft material, and the system wet granular, dry 4 hours of 80-100 degree, the cooling back added folic acid, vitamin D
3, magnesium stearate, pregelatinized Starch mixes, granulate, encapsulated 1,000,000 capsules that obtain.
Embodiment 3:
The preparation of granule
Calcium carbonate 1000kg
Folic acid 202g
Vitamin D
3880g (100,000 IU/g)
Sucrose 200kg
Pregelatinized Starch 10kg
Dextrin 100kg
Calcium carbonate and sucrose, folic acid, vitamin D
3, pregelatinized Starch, dextrin mixes, and the gelatinized corn starch moistening is granulated, granulate, packing obtains 500,000 bag mouth clothes granule.
Embodiment 4:
The preparation of tablet
Calcium gluconate (amounting to into calcium ion) 386kg
Folic acid 202g
Vitamin D
3880g (100,000 IU/g)
Medical starch 100kg
Magnesium stearate 10kg
Pregelatinized Starch 10kg
Calcium gluconate and medical starch mix, the system soft material, and the system wet granular, dry 4 hours of 80-100 degree, the cooling back added folic acid, vitamin D
3, magnesium stearate, pregelatinized Starch mixes, granulate, tabletting, the bag film-coat, packing promptly gets 1,000,000 in tablet.
Embodiment 5:
The preparation of tablet
Citric acid calcium (amounting to into calcium ion) 386kg
Folic acid 202g
Vitamin D
3880g (100,000 IU/g)
Medical starch 100kg
Magnesium stearate 10kg
Pregelatinized Starch 10kg
Citric acid calcium and medical starch mix, the system soft material, and the system wet granular, dry 4 hours of 80-100 degree, the cooling back added folic acid, vitamin D
3, magnesium stearate, pregelatinized Starch mixes, granulate, tabletting, the bag film-coat, packing promptly gets 1,000,000 in tablet.
Claims (10)
1. the medicament of an extra-nutrition is made up of acceptable auxiliary on active component with Nutrition and the pharmaceutics, it is characterized in that, described active component with Nutrition is a folic acid, the combination of vitamin D class material and calcareous material.
2. the medicament of claim 1, there are the active component folic acid 0.1-1.5mg that each dosage unit contains, vitamin D class material 40-180IU with unit dose, calcareous material is calculated as 100-800mg with utilizable calcium, and all the other are acceptable auxiliary on the pharmaceutics.
3. the medicament of claim 1, there are the active component folic acid 0.2-0.8mg that each dosage unit contains, vitamin D class material 60-120IU with unit dose, calcareous material is calculated as 300-400mg with utilizable calcium, and all the other are acceptable auxiliary on the pharmaceutics.
4. the medicament of claim 1 exists with unit dose, the active component folic acid 0.2mg that each dosage unit contains, and vitamin D class material 80IU, calcareous material is calculated as 386mg with utilizable calcium, and all the other are acceptable auxiliary on the pharmaceutics.
5. the medicament of claim 1 is to be fit to oral any dosage form.
6. the medicament of claim 1 is tablet, capsule, granule or oral liquid.
7. the medicament of claim 1 is a tablet.
8. the medicament of claim 1-7, wherein vitamin D class material is a vitamin D
3, calcareous material is selected from calcium carbonate, calcium gluconate, Citric acid calcium, calcium lactate or threonic acid calcium.
9. the medicament of claim 8, wherein calcareous material is a calcium carbonate.
10. the medicament of claim 9, the active component folic acid 0.2mg that each dosage unit contains, vitamin D
380IU, calcium carbonate is calculated as 386mg with utilizable calcium, and all the other are acceptable auxiliary on the pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100339182A CN1247199C (en) | 2004-04-19 | 2004-04-19 | Nutrition supplement agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100339182A CN1247199C (en) | 2004-04-19 | 2004-04-19 | Nutrition supplement agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562036A true CN1562036A (en) | 2005-01-12 |
| CN1247199C CN1247199C (en) | 2006-03-29 |
Family
ID=34481419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100339182A Expired - Lifetime CN1247199C (en) | 2004-04-19 | 2004-04-19 | Nutrition supplement agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1247199C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178019A (en) * | 2010-12-08 | 2011-09-14 | 叶建斌 | Formula of chewable tablets for preventing anemia in pregnant women and preparation method thereof |
| CN104958316A (en) * | 2015-07-21 | 2015-10-07 | 陈�峰 | High-density compound calcium carbonate tablet and preparation method thereof |
| CN106109490A (en) * | 2016-08-02 | 2016-11-16 | 辽宁康辰药业有限公司 | One increases bone density, prevents and treats osteoporotic tablet and preparation method thereof |
| CN106798337A (en) * | 2017-01-18 | 2017-06-06 | 深圳泰乐德营养与健康有限公司 | A kind of nutritious supplementary pharmaceutical suitable for the elderly |
| CN107232611A (en) * | 2017-05-22 | 2017-10-10 | 深圳泰乐德营养与健康有限公司 | A kind of nutrient composition being made up of vitamin D, K and folic acid |
| CN111246753A (en) * | 2017-09-06 | 2020-06-05 | 埃比奥吉恩药物股份公司 | Composition for calcium supplementation |
-
2004
- 2004-04-19 CN CNB2004100339182A patent/CN1247199C/en not_active Expired - Lifetime
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178019A (en) * | 2010-12-08 | 2011-09-14 | 叶建斌 | Formula of chewable tablets for preventing anemia in pregnant women and preparation method thereof |
| CN102178019B (en) * | 2010-12-08 | 2012-09-19 | 叶建斌 | Formula of chewable tablets for preventing anemia in pregnant women and preparation method thereof |
| CN104958316A (en) * | 2015-07-21 | 2015-10-07 | 陈�峰 | High-density compound calcium carbonate tablet and preparation method thereof |
| CN106109490A (en) * | 2016-08-02 | 2016-11-16 | 辽宁康辰药业有限公司 | One increases bone density, prevents and treats osteoporotic tablet and preparation method thereof |
| CN106798337A (en) * | 2017-01-18 | 2017-06-06 | 深圳泰乐德营养与健康有限公司 | A kind of nutritious supplementary pharmaceutical suitable for the elderly |
| CN106798337B (en) * | 2017-01-18 | 2020-12-15 | 深圳芙莱特营养与健康有限公司 | Nutritional supplement suitable for middle-aged and elderly people |
| CN107232611A (en) * | 2017-05-22 | 2017-10-10 | 深圳泰乐德营养与健康有限公司 | A kind of nutrient composition being made up of vitamin D, K and folic acid |
| CN107232611B (en) * | 2017-05-22 | 2021-02-26 | 深圳奥萨制药有限公司 | A nutritional composition comprising vitamin D, K and folic acid |
| CN111246753A (en) * | 2017-09-06 | 2020-06-05 | 埃比奥吉恩药物股份公司 | Composition for calcium supplementation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1247199C (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1191835C (en) | Methods of treamtment of mitochondrial disorders | |
| JP2009513641A5 (en) | ||
| WO2020253835A1 (en) | Nitrate and vitamin-containing composition, preparation method therefor, formulation thereof and use thereof | |
| CN101537050B (en) | Health product capable of enhancing bone density and immune function, and preparation method and applications thereof | |
| CN103202483A (en) | Nutritional composition for calcium supplement | |
| HU226984B1 (en) | Medical and food products for treating diabetes mellitus and process for producing thereof | |
| CN1247199C (en) | Nutrition supplement agent | |
| CN101176734A (en) | Nutrients replenisher for replenishing folic acid and vitamin B12 and preparation method thereof | |
| CN102512437B (en) | Medicinal composition of liposoluble vitamin injection (I) and water-soluble vitamin for injection and preparation method thereof | |
| WO2019034112A1 (en) | COMPOSITION CONTAINING L-CARNITINE AND β-HYDROXYBUTYRATE COMPOUND | |
| CN104068306B (en) | Health food for improving bone density and preparation method of health food | |
| TW202116336A (en) | Use of lactobacillus reuteri gkr1 for preparing composition of reducing uric acid | |
| EP3165221B1 (en) | Blood-fat reducing composition and application thereof | |
| CN1292756C (en) | Effervescence tablet preparation for replenishing nutritious elements to human being and its preparation method | |
| CN101642425A (en) | Folic acid enteric preparation composition and preparation method thereof | |
| CN105581331B (en) | A kind of nutritional composition for calcium supplement | |
| CN104161746A (en) | Sugar-free lysine and gluconic acid zinc granule composition and preparation method thereof | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
| CN101152188B (en) | Vitamin D* solid dispersion peridium patch and method for preparing the same | |
| CN1101684C (en) | Bee pupa calcium preparation | |
| US10894059B2 (en) | NADH compound composition, and preparation and use thereof | |
| CN106036387A (en) | Super chenopodium quinoa willd nutritional packet for promoting growth of children | |
| CN102342400A (en) | High-calcium xylitol | |
| PATRA et al. | A controlled clinical trial of rice and glycine-containing oral rehydration solution in acute diarrhoea in children | |
| CN101277617A (en) | Nutriment containing betaine for curing ischemic muscular atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060329 |